Telix stock: CEO to join UBS biopharma conference

ISIN: AU000000TLX2
WKN: A2H7JK
Frankfurt ticker: T3X
Primary listings: ASX and Nasdaq
Lang &amp; Schwarz quote: 8.45 euros at 20:33 CET on November 13, 2026

Published on 11/13/2026 at 20:37 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Telix stock will feature CEO Christian Behrenbruch at a UBS conference on November 17. The fireside chat will be webcast live.

Telix outlines upcoming investor event

Christian Behrenbruch and Richard Valeix will take part in a UBS Global Biopharma Conference fireside chat.
The session is scheduled for November 17 in London and will be webcast live.
Telix's portfolio includes commercial precision diagnostics and late-stage therapeutic programs.

Telix, AU000000TLX2, Illustration mit AI erstellt.

Telix Pharmaceuticals announced on November 11 that Managing Director and Group CEO Christian Behrenbruch and Richard Valeix, CEO Therapeutics, will participate in the UBS Global Biopharma Conference in London on November 17. The announcement was distributed by Telix through AAP.

Conference puts pipeline in view

The executives are scheduled to take part in a fireside chat at 9:20 a.m. GMT. Telix said the session will be webcast live through its investor-relations website, giving investors access to management commentary on the company's commercial and development activities.

Telix describes itself as a commercial-stage radiopharmaceutical company focused on targeted theranostics. Its commercial portfolio includes Illuccix, Gozellix and Pixclara, while its late-stage therapeutic pipeline includes TLX591-Tx for prostate cancer, TLX101-Tx for recurrent glioblastoma and TLX250-Tx for kidney cancer.